«Al ser el primer biosimilar de pertuzumab, y actualmente el único, en Europa, la autorización de POHERDY por parte de la Comisión Europea supone un avance importante para ampliar el acceso a los ...
SHANGHÁI, China, y JERSEY CITY, Nueva Jersey, April 30, 2026--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) y Organon (NYSE: OGN) han anunciado hoy que la Comisión Europea (CE) ha ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The healthcare sector has produced some of its most dramatic single-stock moves over the past month, with the top 10 performers posting gains ranging from 38% to a staggering 116%, a surge driven by a ...
Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. BeOne Medicines is joining the PD-1xVEGF race with an option for a trispecific ...
On April 26, 2026, Sun Pharmaceutical Industries Limited (“Sun Pharma”) and Organon & Co. (“Organon”) announced an agreement for Sun Pharma to acquire all outstanding shares of Organon in an all-cash ...
Sun Pharmaceutical Industries' landmark $11.75 billion acquisition of US-based Organon & Co is set to strategically expand its portfolio into high-growth women's health and biosimilars segments, ...
More Bonds of Organon & Co./ Organon Foreign Debt Co-Issuer B.V. About the Organon & Co./ Organon Foreign Debt Co-Issuer B.V.-Bond (XS2332250708) The Organon & Co./ Organon Foreign Debt Co-Issuer B.V.
The composer Cinco Paul discusses the clever references to classic musicals everywhere you look (and hear) in his new ...
The Cleveland Orchestra’s recent performances of Beethoven’s “Fidelio” join concerts that fill a gap in American opera.
Sun Pharma’s $11.75-billion acquisition of Organon & Co. is likely to push Indian pharmaceutical companies to evaluate larger overseas acquisitions as the sector looks to expand beyond generics into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results